Bisphosphonates for the Treatment of Calcinosis Cutis—A Retrospective Single-Center Study

(1) Background: Calcinosis cutis is a frequent symptom of autoimmune connective tissue diseases leading to pain, transcutaneous expulsion of calcified material and bacterial superinfection. There is a high need for new therapeutic options as no standardized treatment algorithm is established. While...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lilian Rauch, Rüdiger Hein, Tilo Biedermann, Kilian Eyerich, Felix Lauffer
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	calcinosis cutis bisphosphonates pamidronate autoimmune connective tissue diseases systemic sclerosis dermatomyositis Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/a06cbcd0945f4199b9d5fd8bc320d893
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a06cbcd0945f4199b9d5fd8bc320d893
record_format	dspace
spelling	oai:doaj.org-article:a06cbcd0945f4199b9d5fd8bc320d8932021-11-25T16:50:57ZBisphosphonates for the Treatment of Calcinosis Cutis—A Retrospective Single-Center Study10.3390/biomedicines91116982227-9059https://doaj.org/article/a06cbcd0945f4199b9d5fd8bc320d8932021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1698https://doaj.org/toc/2227-9059(1) Background: Calcinosis cutis is a frequent symptom of autoimmune connective tissue diseases leading to pain, transcutaneous expulsion of calcified material and bacterial superinfection. There is a high need for new therapeutic options as no standardized treatment algorithm is established. While case reports indicate beneficial effects of bisphosphonates, standardized evaluation of treatment effects is missing. (2) Methods: In this retrospective analysis we evaluate the effects of intravenous pamidronate, a second-generation bisphosphonate, in seven patients with calcinosis cutis using consecutive clinical pictures, radiological examinations and patient’s subjective evaluation. (3) Results: 5/6 patients reported a reduction of pain, improvement of general condition and cessation of calcinosis progression. Regression of skin lesions was detectable in clinical pictures of 2/6 patients, while 1/6 patients had stable disease. Radiological examination revealed improvement or stable disease in 3/5 patients. Fever was the most common side effect. One out of seven patients developed osteonecrosis of the jaw. (4) Conclusions: Bisphosphonates appear to have beneficial effects in a subgroup of calcinosis cutis patients. While patient’s subjective evaluation was mainly positive, objective assessments showed improvement in approximately half of the cases. With regard to potential severe side effects, a careful risk-benefit evaluation is necessary before treatment initiation.Lilian RauchRüdiger HeinTilo BiedermannKilian EyerichFelix LaufferMDPI AGarticlecalcinosis cutisbisphosphonatespamidronateautoimmune connective tissue diseasessystemic sclerosisdermatomyositisBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1698, p 1698 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	calcinosis cutis bisphosphonates pamidronate autoimmune connective tissue diseases systemic sclerosis dermatomyositis Biology (General) QH301-705.5
spellingShingle	calcinosis cutis bisphosphonates pamidronate autoimmune connective tissue diseases systemic sclerosis dermatomyositis Biology (General) QH301-705.5 Lilian Rauch Rüdiger Hein Tilo Biedermann Kilian Eyerich Felix Lauffer Bisphosphonates for the Treatment of Calcinosis Cutis—A Retrospective Single-Center Study
description	(1) Background: Calcinosis cutis is a frequent symptom of autoimmune connective tissue diseases leading to pain, transcutaneous expulsion of calcified material and bacterial superinfection. There is a high need for new therapeutic options as no standardized treatment algorithm is established. While case reports indicate beneficial effects of bisphosphonates, standardized evaluation of treatment effects is missing. (2) Methods: In this retrospective analysis we evaluate the effects of intravenous pamidronate, a second-generation bisphosphonate, in seven patients with calcinosis cutis using consecutive clinical pictures, radiological examinations and patient’s subjective evaluation. (3) Results: 5/6 patients reported a reduction of pain, improvement of general condition and cessation of calcinosis progression. Regression of skin lesions was detectable in clinical pictures of 2/6 patients, while 1/6 patients had stable disease. Radiological examination revealed improvement or stable disease in 3/5 patients. Fever was the most common side effect. One out of seven patients developed osteonecrosis of the jaw. (4) Conclusions: Bisphosphonates appear to have beneficial effects in a subgroup of calcinosis cutis patients. While patient’s subjective evaluation was mainly positive, objective assessments showed improvement in approximately half of the cases. With regard to potential severe side effects, a careful risk-benefit evaluation is necessary before treatment initiation.
format	article
author	Lilian Rauch Rüdiger Hein Tilo Biedermann Kilian Eyerich Felix Lauffer
author_facet	Lilian Rauch Rüdiger Hein Tilo Biedermann Kilian Eyerich Felix Lauffer
author_sort	Lilian Rauch
title	Bisphosphonates for the Treatment of Calcinosis Cutis—A Retrospective Single-Center Study
title_short	Bisphosphonates for the Treatment of Calcinosis Cutis—A Retrospective Single-Center Study
title_full	Bisphosphonates for the Treatment of Calcinosis Cutis—A Retrospective Single-Center Study
title_fullStr	Bisphosphonates for the Treatment of Calcinosis Cutis—A Retrospective Single-Center Study
title_full_unstemmed	Bisphosphonates for the Treatment of Calcinosis Cutis—A Retrospective Single-Center Study
title_sort	bisphosphonates for the treatment of calcinosis cutis—a retrospective single-center study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a06cbcd0945f4199b9d5fd8bc320d893
work_keys_str_mv	AT lilianrauch bisphosphonatesforthetreatmentofcalcinosiscutisaretrospectivesinglecenterstudy AT rudigerhein bisphosphonatesforthetreatmentofcalcinosiscutisaretrospectivesinglecenterstudy AT tilobiedermann bisphosphonatesforthetreatmentofcalcinosiscutisaretrospectivesinglecenterstudy AT kilianeyerich bisphosphonatesforthetreatmentofcalcinosiscutisaretrospectivesinglecenterstudy AT felixlauffer bisphosphonatesforthetreatmentofcalcinosiscutisaretrospectivesinglecenterstudy
_version_	1718412913009491968

Bisphosphonates for the Treatment of Calcinosis Cutis—A Retrospective Single-Center Study

Ejemplares similares